FUJIFILM Diosynth Biotechnologies vs Wacker Biotech: CDMO Comparison
How does FUJIFILM Diosynth Biotechnologies compare to Wacker Biotech for mRNA/LNP manufacturing?
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Wacker Biotech on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- FUJIFILM Diosynth Biotechnologies maintains 6 MHRA / UK GMP certificates; Wacker Biotech does not.
On a 13-modality CDMO landscape, both FUJIFILM Diosynth Biotechnologies and Wacker Biotech qualify as mRNA/LNP manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both FUJIFILM Diosynth Biotechnologies and Wacker Biotech qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs Wacker Biotech
How does FUJIFILM Diosynth Biotechnologies compare to Wacker Biotech for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, FUJIFILM Diosynth Biotechnologies is 85/100 and Wacker Biotech is 82/100; European coverage is 23 active EMA+MHRA certificates for FUJIFILM Diosynth Biotechnologies vs 13 for Wacker Biotech. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
How do FUJIFILM Diosynth Biotechnologies and Wacker Biotech compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 17 active EMA GMP certificates and 6 MHRA / UK certificates. Wacker Biotech holds 13 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — FUJIFILM Diosynth Biotechnologies or Wacker Biotech?
Both FUJIFILM Diosynth Biotechnologies and Wacker Biotech are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 85/100 and Wacker Biotech carries 82/100 — essentially tied for FUJIFILM Diosynth Biotechnologies. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →